Androgen receptor

The androgen receptor (AR), also known as NR3C4 (nuclear receptor subfamily 3, group C, member 4), is a type of nuclear receptor that is activated by binding either of the androgenic hormones, testosterone, or dihydrotestosterone in the cytoplasm and then translocating into the nucleus. The androgen receptor is most closely related to the progesterone receptor, and progestins in higher dosages can block the androgen receptor.

The main function of the androgen receptor is as a DNA-binding transcription factor that regulates gene expression; however, the androgen receptor has other functions as well. Androgen regulated genes are critical for the development and maintenance of the male sexual phenotype.

Function

Effect on development

In some cell types, testosterone interacts directly with androgen receptors, whereas, in others, testosterone is converted by 5-alpha-reductase to dihydrotestosterone, an even more potent agonist for androgen receptor activation. Testosterone appears to be the primary androgen receptor-activating hormone in the Wolffian duct, whereas dihydrotestosterone is the main androgenic hormone in the urogenital sinus, urogenital tubercle, and hair follicles. Hence, testosterone is responsible primarily for the development of male primary sexual characteristics, whereas dihydrotestosterone is responsible for secondary male characteristics.

Podcasts:

PLAYLIST TIME:

Latest News for: androgen receptor

Edit

Study Focuses on Resistance to Androgen Receptor-Targeted Therapy in Advanced Prostate Cancer (Texas Tech University Health Sciences Center)

Public Technologies 29 Mar 2025
This is an abstract of the document. To keep reading, click here and get access to the original version ... Disclaimer ... (noodl. 123346494) .
Edit

Top News | Radioligand Therapy Market Set to Reach $13 Billion with ~5% CAGR by 2030

Pharmiweb 25 Mar 2025
... membrane antigen (PSMA)-targeted radioligand therapy (RLT), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor (ARPI).
Edit

Angle PLC Announces Results of Eisai Phase 2 pilot study

ACCESSWIRE 21 Mar 2025
Development of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay successfully completed for AstraZeneca.
Edit

Zydus Lifesciences gets USFDA nod to produce prostate cancer treatment drug

The Times of India 18 Mar 2025
Apalutamide, an androgen receptor inhibitor, is intended for metastatic ...
Edit

Metastatic Prostate Cancer Pipeline 2024: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by ...

GetNews 14 Mar 2025
In November 2024, The US Food and Drug Administration (FDA) has accepted Bayer’s supplemental new drug application (sNDA) for its oral androgen receptor inhibitor (ARi), Nubeqa (darolutamide), ...
  • 1
×